Pulmonary fibrosis biotechnology company Avalyn Pharma (AVLN.US) prices IPO at $18, raising $300 million, to debut on Nasdaq tonight

老虎证券2026/04/30 07:03

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

The company raised $300 million by issuing 16.7 million shares at a price of $18 per share, with the pricing set at the upper limit of the prior range of $16 to $18 per share. The company initially planned to issue 11.8 million shares, also within the pricing range of $16 to $18 per share, but expanded the issuance size on April 29. Based on this pricing, the company's fully diluted market capitalization will reach $813 million. Avalyn's stock is expected to officially begin trading on the Nasdaq Global Select Market on Thursday, April 30.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

In an email, NVIDIA's new Chairman of the Board Harvey Jones stated that the board takes its duty as guardian of this great company very seriously. The company's strength comes from our employees, leadership team, technological capabilities, and partner ecosystem. We will continue to drive business growth and lead the industry forward. Thank you all for your focus, professionalism, and dedication to NVIDIA.

华尔街见闻•2026/11/12 19:11